Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Telescope Innovations Corp ( (TSE:TELI) ) has provided an announcement.
Telescope Innovations Corp. reported revenues of $1.2 million for Q1 2025, driven by the success of its DirectInject-LC™ product and strategic reinvestments to foster growth, despite an adjusted EBITA loss of $103K. The company has expanded its market presence through global distribution agreements and strategic collaborations, notably with Pfizer on Self-Driving Labs and advancements in lithium refining technology, positioning it as a leader in innovation and strategic partnerships.
More about Telescope Innovations Corp
Telescope Innovations Corp. is a developer of advanced technologies and services for the global pharmaceutical and chemical industries, focusing on products like DirectInject-LC™ and innovative solutions such as Self-Driving Laboratories and ReCRFT™ technology.
YTD Price Performance: 2.44%
Average Trading Volume: 18,318
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$22.54M
For detailed information about TELI stock, go to TipRanks’ Stock Analysis page.
